All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
GvHD Hub Chair Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, provides the highlights for GvHD from the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
ASH 2020: Highlights for GvHD
Mohty focuses on topics that, in his opinion, will make an important difference in the management of chronic GvHD. He underlines key findings from studies evaluating ruxolitinib and the novel agent belumosudil (KD025) for the treatment of chronic GvHD.
Subscribe to get the best content related to GvHD delivered to your inbox